[Federal Register Volume 71, Number 77 (Friday, April 21, 2006)]
[Notices]
[Page 20729]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-5966]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 12, 2005, Guilford 
Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, MD 21224, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Cocaine (9041), a basic class 
of controlled substance listed in Schedules II.
    The company plans to manufacture a cocaine derivative to be used in 
clinical research studies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
VA 22301; and must be filed no later than June 20, 2006.

    Dated: April 17, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-5966 Filed 4-20-06; 8:45 am]
BILLING CODE 4410-09-P